Johnson & Johnson (JNJ.DE)
| Previous close | 136.10 |
| Open | 136.08 |
| Bid | 136.04 x 0 |
| Ask | 136.20 x 0 |
| Day's range | 135.62 - 136.30 |
| 52-week range | 132.78 - 161.20 |
| Volume | |
| Avg. volume | 3,503 |
| Market cap | 327.841B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 21.68 |
| EPS (TTM) | 6.27 |
| Earnings date | 17 July 2024 |
| Forward dividend & yield | 4.55 (3.34%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
PR NewswireSubcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) for all currently approved or submitted indications of intravenous (IV) RYBREVANT® (amivantamab-vmjw) in certain patients with non-small cell lung cancer (NSCLC).
PR NewswireLate-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the Phase 2 DAHLIAS dose-ranging study of nipocalimab in adult patients living with Sjögren's disease (SjD). Response was demonstrated as early as Week 4 and continued to increase throughout the 24-week treatment period compared with patients recei
ZacksJohnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
